Ines Ushiro-Lumb

Ines Ushiro-Lumb

Auto-generated profile, based on publicly available information

Ines Ushiro-Lumb

Organ and Tissue Donation and Transplantation NHS Blood and Transplant (NHSBT) London UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2023 in Nature
Verified
Journal Article
Open access
PDF file
SMSofia Morfopoulou
Sofia Morfopoulou
SBSarah Buddle
Sarah Buddle
OMOscar Enrique Torres Montaguth
Oscar Enrique Torres Montaguth
LALaura Atkinson
Laura Atkinson
JGJosé Afonso Guerra-Assunção
José Afonso Guerra-Assunção
JBJudith Breuer
Judith Breuer
Since its first identification in Scotland, over 1,000 cases of unexplained paediatric hepatitis in children have been reported worldwide, including 278 cases in the UK1. Here we report an investigation of 38 cases, 66 age-matched immunocompetent controls and 21 immunocompromised comparator participants, using a combination of genomic, transcriptomic, proteomic and immunohistochemical methods. We detected high levels of adeno-associated virus 2 (AAV2) DNA in the liver, blood, plasma or stool from 27 of 28 cases. We found low levels of adenovirus (HAdV) and human herpesvirus 6B (HHV-6B) in 23 of 31 and 16 of 23, respectively, of the cases tested. By contrast, AAV2 was infrequently detected and at low titre in the blood or the liver from control children with HAdV, even when profoundly immunosuppressed. AAV2, HAdV and HHV-6 phylogeny excluded the emergence of novel strains in cases. Histological analyses of explanted livers showed enrichment for T cells and B lineage cells. Proteomic comparison of liver tissue from cases and healthy controls identified increased expression of HLA class 2, immunoglobulin variable regions and complement proteins. HAdV and AAV2 proteins were not detected in the livers. Instead, we identified AAV2 DNA complexes reflecting both HAdV-mediated and HHV-6B-mediated replication. We hypothesize that high levels of abnormal AAV2 replication products aided by HAdV and, in severe cases, HHV-6B may have triggered immune-mediated hepatic disease in genetically and immunologically predisposed children.

19 July 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
GGGeorge H.B. Greenhall
George H.B. Greenhall
IUInes Ushiro-Lumb
Ines Ushiro-Lumb
SPSue Pavord
Sue Pavord
ICIan Currie
Ian Currie
MPM. Thamara P.R. Perera
M. Thamara P.R. Perera
JFJohn Forsythe
John Forsythe

4 September 2023 in Transplant International
Verified
Journal Article
Open access
IUInes Ushiro-Lumb
Ines Ushiro-Lumb
JFJohn Forsythe
John Forsythe
BHBecky Haywood
Becky Haywood
CGChristie Geoghegan
Christie Geoghegan
VMVictoria Maddox
Victoria Maddox
DTDouglas Thorburn
Douglas Thorburn
Universal Hepatitis E Virus (HEV) screening of deceased organ donors was implemented by the UK national organ procurement organisation in October 2017. Donor testing for HEV infection is done post-transplant; detection of HEV ribonucleic acid (RNA) in donor plasma is therefore not a contra-indication for organ donation, with the result being used to inform recipient management. Immediate post-transplant detection of donor HEV viraemia triggers notification to transplant centres. Follow up of liver and kidney recipients has shown that transmission through solid organs is very efficient, particularly through liver grafts, as expected; no other organ types were transplanted in this cohort. Although donors with higher plasma viral load (VL > 103 IU/mL) were invariably associated with recipient infection, transmission was also documented at lower VL levels. Knowledge of donor HEV status has led to identification of transmission of infection via solid organ grafts followed by close patient monitoring and informed clinical management decisions. The purpose of this strategy is to allow early detection of infection and recurrence and treatment to circumvent the risk of accelerated liver damage from chronic HEV infection due to undiagnosed, inadvertent donor-derived transmission of infection.

2 January 2025 in Journal of Infection
Verified
Journal Article
Open access
APAlessia Dalla Pria
Alessia Dalla Pria
IUInes Ushiro-Lumb
Ines Ushiro-Lumb
PBProfessor Mark Bower
Professor Mark Bower
In solid organ transplant recipients (SOTRs), the oncogenic virus human herpesvirus-8 (HHV-8) also named Kaposi sarcoma herpesvirus (KSHV) causes four clinical diseases: Kaposi Sarcoma, Primary Effusion Lymphoma, Multicentric Castleman Disease (MCD), and KSHV inflammatory cytokine syndrome (KICS). This review outlines these clinical scenarios and discusses their management. Although HHV8 related disease in SOTR was first described more than three decades ago, there is a lack of data on treatment so much of the guidance is based on evidence in other immunodeficient patients, particularly people living with HIV. Whilst reduction of immunosuppression and switch from calcineurin inhibitors to mTOR inhibitors may be sufficient in early stage post-transplant KS, systemic chemotherapy is necessary for advanced stage KS and in KSHV related lymphomas. For MCD and KICS,which usually follow primary HHV-8 infection, rituximab based immunochemotherapy regimens are the cornerstone of treatment for these potentially lethal diseases. Although HHV-8 infection in SOTR is well recognised it remains under reported and greater awareness of the different clinical presentations of HHV-8 in this context is fundamental to improve outcomes.

18 October 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
AHAngus Hann
Angus Hann
HHHermien Hartog
Hermien Hartog
ANAnisa Nutu
Anisa Nutu
KQKatherine Quist
Katherine Quist
RSRebecca Sanabria-Mateos
Rebecca Sanabria-Mateos
MPM. Thamara P.R. Perera
M. Thamara P.R. Perera
Click on the article title to read more.

18 May 2022 in Transplantation
Verified
Journal Article
Closed access
IUInês Ushiro-Lumb
Inês Ushiro-Lumb
CCChris J. Callaghan
Chris J. Callaghan
GPGavin J. Pettigrew
Gavin J. Pettigrew
SMSusanna Madden
Susanna Madden
LMLisa Mumford
Lisa Mumford
OTon behalf of the NHSBT Organ and Tissue Donation and Transplantation Clinical Team
on behalf of the NHSBT Organ and Tissue Donation and Transplantation Clinical Team